Шадривова о в аспергиллез

Обновлено: 01.05.2024

Ключевые слова

Об авторах

Ольга Витальевна Шадривова

194291 Санкт-Петербург, ул. Сантьяго де Куба, 1/28

197022 Санкт-Петербург, ул. Льва Толстого, 6–8

Список литературы

2. Skiada A., Lass-Floerl C., Klimko N. et al. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol 2018;56(Suppl 1):93–101. DOI: 10.1093/mmy/myx101. PMID: 29538730.

3. Tissot F., Agrawal S., Pagano L. et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017;102(3):433–44. DOI: 10.3324/haematol.2016.152900. PMID: 28011902.

4. Ullmann A.J., Aguado J.M., ArikanAkdagli S. et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018;24(Suppl 1):e1–38. DOI: 10.1016/j.cmi.2018.01.002. PMID: 29544767.

5. De Pauw B., Walsh T.J., Donnelly J.P. et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases 2008;46(12):1813–21. DOI: 10.1086/588660. PMID: 18462102.

6. Lewis R.E., Cahyame-Zuniga L., Leventakos K. et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses 2013;56(6):638–45. DOI: 10.1111/myc. 12081. PMID: 23551865.

8. Kontoyiannis D.P., Marr K.A., Park B.J. et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010;50(8):1091–100. DOI: 10.1086/651263. PMID: 20218877.

9. Kurosawa M., Yonezumi M., Hashino S. et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 2012;96(6):748–57. DOI: 10.1007/s12185-012-1210-y. PMID: 23111539.

10. Kontoyiannis D., Hongbo Y., Jinlin S. et al. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis 2016;16(1):730. DOI: 10.1186/s12879-016-2023-z. PMID: 27905900.

11. Lanternier F., Dannaoui E., Morizot G. et al. A global analysis of mucormycosis in France: The RetroZygo Study (2005– 2007). Clin Infect Dis 2012;54(Suppl 1): S35–43. DOI: 10.1093/cid/cir880. PMID: 22247443.

12. Lestrade P., van der Velden W., Bouwman F. et al. Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a singlecentre retrospective cohort study. J Antimicrob Chemother 2018;73(5):1389–94. DOI: 10.1093/jac/dkx527. PMID: 29394399.

13. Babor F., Schuster F., Mackenzie C. et al. Invasive aspergillosis in pediatric oncology patients: a rare event with poor prognosiscase analysis to plan better targeted prophylactic or therapeutic measurement. Klin Padiatr 2012;224(3):160–5. DOI: 10.1055/s-0032-1304625. PMID: 22504775.

14. Guinea J., Escribano P., Vena A. et al. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: epidemiology and microbiological characterization of the isolates.PLoS ONE 2017;12(6):e0179136. DOI: 10.1371/journal.pone. 0179136. PMID: 28591186.

15. Hammond S.P., Baden L.R., Marty F.M. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother 2011;55(11):5018–21. DOI: 10.1128/AAC.00536–11. PMID: 21876046.

16. Lafaurie M., Lapalu J., Raffoux E. et al. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Clin Microbiol Infect 2010;16(8):1191–6. DOI: 10.1111/j.1469-0691.2009.03050.x. PMID: 19735276.

17. Steinbach W.J., Marr K.A., Anaissie E.J. et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH alliance registry. J Infect 2012;65(5):453–64. DOI: 10.1016/j.jinf.2012.08.003. PMID: 22898389.

18. Klimko N.N., Khostelidi S.N., Popova M.O. et al. Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia. Mycoses 2014;57 (Suppl 3):91–6. DOI: 10.1111/myc.12247. PMID: 25187314.

21. Nicolle M.C., Bénet T., Thiebaut A. et al. Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004to 2009. Haematologica 2011;96(11):1685–91. DOI: 10.3324/haematol. 2011.044636. PMID: 21791468.

22. Jung J., Kim Y., Lee H.J. et al. Comparison of computed tomographic ﬁndings in pulmonary mucormycosis and invasive pulmonary aspergillosis. Clin Microbiol Infect 2015;21(7):684. DOI: 10.1016/j. cmi. 2015.03.019. PMID: 25882362.

24. Georgiadou S.P., Sipsas N.V., Marom E.M., Kontoyiannis D.P.The diagnostic value of halo and reversed halo signs for invasive mold infectionsin compromised hosts. Clin Infect Dis 2011;52(9): 1144–55. DOI: 10.1093/cid/cir122. PMID: 21467021.

25. Pagano L., Caira M., Candoni A. et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010;95(4):644–50. DOI: 10.3324/haematol.2009.012054. PMID: 19850903.

26. Cho S.Y., Lee D.G., Choi J.K. et al. Characteristics of culture-positive invasive pulmonary aspergillosis in patients with hematologic diseases: comparison between Aspergillus fumigatus and non-fumigatus Aspergillus species. Medicine (Baltimore) 2017;96(49):e8841. DOI: 10.1097/MD.0000000000008841. PMID: 29245249.

27. Herbrecht R., Patterson T.F., Slavin M.A. et al. Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin b for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization forResearch and Treatment of Cancer Infectious Diseases Group. Clin Infect Dis 2015;60(5):713–20. DOI: 10.1093/cid/ciu911. PMID: 25414266.

28. Maertens J.A., Raad I.I., Marr K.A. et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016;387(10020):760–9. DOI: 10.1016/S0140-6736(15)01159-9. PMID: 26684607.

Грибы рода Aspergillus чрезвычайно широко распространены в природе. Ежедневно люди вдыхают до нескольких тысяч спор микромицетов, однако эффективный иммунный ответ предотвращает развитие заболевания. При нарушении механизмов врожденного и адаптивного иммунного ответа в результате генетических дефектов или ятрогенной иммуносупрессии Aspergillus spp. становятся патогенными и способны вызывать тяжелые инвазивные инфекции у иммуноскомпрометированных больных. Тем не менее, в настоящее время не существует надежных биомаркеров, позволяющих прогнозировать риск развития инвазивного аспергиллеза. В обзоре представлены наиболее важные генетические и иммунологические факторы, влияющие на восприимчивость к Aspergillus spp. Знание этих факторов может обеспечить индивидуальный подход к противогрибковой профилактике и терапии у иммуноскомпрометированных пациентов.

Ключевые слова

Об авторах

Северо-Западный государственный медицинский университет им. И.И. Мечникова
Россия
Шадривова Ольга Витальевна – ассистент кафедры клинической микологии, аллергологии и иммунологии, кандидат медицинских наук

Северо-Западный государственный медицинский университет им. И.И. Мечникова
Россия
Фролова Екатерина Васильевна – заведующая НИЛ иммунологии и аллергологии Научно-исследовательского института медицинской микологии им. П.Н. Кашкина, кандидат медицинских наук

Северо-Западный государственный медицинский университет им. И.И. Мечникова
Россия
Тараскина Анастасия Евгеньевна – заведующая НИЛ молекулярно-генетической микробиологии Научно-исследовательского института медицинской микологии им. П.Н. Кашкина, кандидат биологичеких наук

Северо-Западный государственный медицинский университет им. И.И. Мечникова
Россия
Климко Николай Николаевич – заведующий кафедрой клинической микологии, аллергологии и иммунологии, доктор медицинских наук, профессор

Список литературы

1. Klimko N., Kozlova Y., Khostelidi S., et al. The burden of serious fungal diseases in Russia // Mycoses, 2015, 58 (Suppl. S5), 58–62.

2. Pagano L., Caira M., Candoni A., et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study // Haematologica. 2010 Apr;95(4):644-50. doi: 10.3324/haematol.2009.012054.

4. Климко, Н.Н. Инвазивный аспергиллез: результаты многоцентрового исследования / Н.Н. Климко [и др.] // Онкогематология. – 2014. – № 2. – С. 13–19.

5. Segal BH. Aspergillosis. N Engl J Med 2009; 360:1870–84.

6. Vinh DC, Sugui JA, Hsu AP, Freeman AF, Holland SM. Invasive fungal disease in autosomal-dominant hyper-IgE syndrome. J Allergy Clin Immunol 2010; 125:1389–90.

7. Caira M, Girmenia C, Fadda RM, et al. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? Eur J Haematol 2008; 81:242–3.

8. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the TransplantAssociated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091–100.

9. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients:analysis of Multicenter Prospective Antifungal Therapy(PATH) Alliance registry. Clin Infect Dis 2009; 48:265–73.

10. Попова, М. О. Инвазивные микозы при трансплантации гемопоэтических стволовых клеток / М.О. Попова [и др.] // Терапевтический архив. – 2012. – № 7. – С. 50–57.

12. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysisof 18 HIV cohort studies. Lancet 2009; 373:1352–63.

13. Egli A, Humar A, Kumar D. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis 2012; 55:1678–89.

14. Cunha C, Aversa F, Romani L, Carvalho A. Human genetic susceptibility to invasive aspergillosis. PLoS Pathog 2013; 9:e1003434.

15. Wojtowicz A, Bochud PY. Host genetics of invasive Aspergillus and Candida infections. Semin Immunopathol. 2015;37:173–86.

16. Oliveira-Coelho A, Rodrigues F, Campos A Jr, et al. Paving the way for predictive diagnostics and personalized treatment of invasive aspergillosis. Front Microbiol. 2015 May 5;6:411. doi: 10.3389/fmicb.2015.00411. eCollection 2015.

17. Romani L. Immunity to fungal infections. Nat Rev Immunol 2011; 11: 275-288.

18. Camargo JF, Husain S. Immune correlates of protection in human invasive aspergillosis. Clin Infect Dis 2014; 59: 569-77.

19. Moalli F, Doni A, Deban L, et al. Role of complement and Fcγ receptors in the protective activity of the long pentraxin PTX3 against Aspergillus fumigatus. Blood 2010; 116:5170–80.

20. Cunha C, Aversa F, Lacerda JF, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med 2014; 370:421–32. DOI:16.3517.36.

21. Biagi E, Col M, Migliavacca M, et al. PTX3 as a potential novel tool for the diagnosis and monitoring of pulmonary fungal infections in immuno-compromised pediatric patients. J Pediatr Hematol Oncol 2008; 30:881–5. DOI:10.1097/MPH.0b013e318180bc1d

22. Camargo Jose F., Bhimji A, Deepali Kumar, Rupert Kaul, Impaired T Cell Responsiveness to Interleukin-6 in Hematological Patients with Invasive Aspergillosis PLoS One. 2015 DOI:10.1371

23. Rivera A, Hohl TM, Collins N, et al. Dectin-1 diversifies Aspergillus fumigatus-specific T cell responses by inhibiting T helper type 1 CD4T cell differentiation. J Exp Med 2011; 208:369–81

24. Werner JL, Metz AE, Horn D, et al. Requisite role for the dectin-1 beta glucan receptor in pulmonary defense against Aspergillus fumigatus. J Immunol 2009; 182:4938–46.

25. Cunha C, Di IM, Bozza S, et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipientand donor dependent mechanisms of antifungal immunity. Blood 2010; 116:5394–402.

26. Sainz J, Lupianez CB, Segura-Catena J, et al. Dectin-1 and DC-SIGN polymorphisms associated with invasive pulmonary aspergillosis infection.PLoS One 2012; 7:e32273.

27. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med2008; 359:1766–77.

28. Fischer M, Spies-Weisshart B,Schrenk K, et al. Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia. PLoS One.2016 Mar 10;11(3):e0150632. doi: 10.1371/journal.pone.0150632. eCollection 2016.

29. Chamilos G, Ganguly D, Lande R, et al. Generation of IL23 producing dendritic cells (DCs) by airborne fungi regulates fungal pathogenicity via the induction of TH-17 responses. PLoS One 2010; 5:e12955.

30. Smith NL, Denning DW. Clinical implications of interferon-γ genetic and epigenetic variants.Immunology.2014 Dec;143(4):499-511. doi: 10.1111/imm.12362.

31. Lupianez CB, Canet LM, Carvalho A. Polymorphisms in host immunity modulating genes and risk of invasive aspergillosis: Results from the aspBIOmics consortium Infect Immun. 2015 Dec 14;84(3):643-57.

32. Stuehler C, Khanna N, Bozza S, et al. Cross protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood 2011; 117: 5881-91.

33. Pelletier M., Maggi L., Micheletti A. et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 2010; 115:335–43.

34. Kim CJ, McKinnon LR, Kovacs C, et al. Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J Immunol 2013; 191:2164–73.

35. Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood 2013; 121:2402–14.

36. Carvalho A, Cunha C, Di IM, et al. Prognostic signiﬁcance of genetic variantsin the IL-23/Th17 pathway for the outcome of T cell-depleted allogeneic stem cell transplantation. Bone Marrow Transplant 2010;45:1645–52. doi: 10.1038/bmt.2010.28.

37. Milner JD, Brenchley JM, Laurence A, et al. Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452:773–6.

39. Sainz J, Hassan L, Perez E, et al. Interleukin-10 promoter polymorphism as risk factor to develop invasive pulmonary aspergillosis. Immunol Lett. 2007; 109:76–82. DOI:10.1016.2007.01.005

40. Hebart, H. Analysis of T cell responses to Aspergillus fumigates antigens in healthy individuals and patients with hematologic malignancies / H. Hebart, Bollinger, C. Fisch P., [et al.] // Blood. – 2002. – Vol. 100. – P.4521-4528.

42. Jolink H, Hagedoorn RS, Lagendijk EL, et al. Induction of A. fumigates specific CD4+ T cells in patients recovering from invasive aspergillosis. Haematologica 2014 Jul; 99(7): 1255–1263.

43. Stuehler C, Kuenzli E, Veronika K. Jaeger, et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation and association with occurrence and outcome of invasive aspergillosis. J Infect Dis. 2015 Sep 15;212(6):959-67

44. Фролова, Е.В. Прогностическое значение иммунологических показателей у гематологических больных инвазивным аспергиллезом / Е.В. Фролова [и др.] // Проблемы медицинской микологии. – 2014. – Vol. 16, № 3. – С. 37–44.

45. Шадривова, О.В. Прогностическое значение иммунологических показателей у реципиентов трансплантатов аллогенных гемопоэтических стволовых клеток c инвазивным аспергиллезом / О.В. Шадривова [и др.] // Проблемы медицинской микологии. – 2015. – Vol. 17, № 1. – С. 14– 20.

46. Delsing CE, Becker KL, Simon A., et al. Th17 cytokine deficiency in patients with Aspergillus skull base osteomyelitis. BMC Infect Dis. 2015 Mar 21;15:140. doi: 10.1186/s12879-015-0891-2

47. Khanna N, Stuehler C, Lunemann A., et al. Host response to fungal infections -how immunology and host genetics could help to identify and treat patients at risk. Swiss Med Wkly. 2016 Sep 21;146:w14350. doi: 10.4414/smw.2016.14350.

48. Kumaresan P.R., Manuri P.R., Albert N.D. et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection // PNAS. 2014. V. 111. № 29. P. 10660-10665. DOI: 10.1073/pnas.1312789111.